Usability and acceptability of oral fluid hepatitis C self-testing among people who inject drugs in Coastal Kenya: a cross-sectional pilot study.
Diagnosis
HCV
Oral fluid
PWID
Self-testing
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
15 Sep 2022
15 Sep 2022
Historique:
received:
30
11
2021
accepted:
22
08
2022
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
20
9
2022
Statut:
epublish
Résumé
People who inject drugs (PWID) are disproportionally affected by hepatitis C virus (HCV) infection and many remain undiagnosed. HCV self-testing (HCVST) may be an effective approach to increase testing uptake, but has rarely been used among PWID. We assessed the usability and acceptability of HCVST among PWID in Kenya. We conducted a cross-sectional study nested within a cohort study between August and December 2020 on Kenya's North Coast region. Participants were handed a prototype oral fluid HCVST kit and asked to conduct the test relying on the instructions for use. Usability was assessed by documenting errors made and difficulties faced by participants. Acceptability was assessed using an interviewer-administered semi-structured questionnaire. Among 150 participants, 19% were female and 65.3% had primary level education or lower. 71.3% made at least one error, 56.7% experienced some difficulty during at least one step, and the majority of participants (78%) required assistance during at least one step of the procedure. Most common errors occurred when placing the tube into the stand (18%), collecting the oral fluid sample (24%) and timing of reading results (53%). There was a strong association between presence of symptoms of opiate withdrawals and observed errors (94% vs 62%; p = 0.016) in a sub-group of 74 participants assessed. Inter-reader and inter-operator concordance were 97.7% (kappa: 0.92) and 99.2% (kappa: 0.95), respectively. Acceptability assessed by asking whether participants would choose to use HCVST prior to and after conducting HCVST was 98% and 95%, respectively. We found a high acceptability of oral fluid HCVST among PWID. User errors were common and were associated with the presence of withdrawal symptoms among users. Despite errors, most participants were able to obtain and interpret results correctly. These findings suggest that this group of users may benefit from greater messaging and education including options to receive direct assistance when self-testing for HCV.
Sections du résumé
BACKGROUND
BACKGROUND
People who inject drugs (PWID) are disproportionally affected by hepatitis C virus (HCV) infection and many remain undiagnosed. HCV self-testing (HCVST) may be an effective approach to increase testing uptake, but has rarely been used among PWID. We assessed the usability and acceptability of HCVST among PWID in Kenya.
METHODS
METHODS
We conducted a cross-sectional study nested within a cohort study between August and December 2020 on Kenya's North Coast region. Participants were handed a prototype oral fluid HCVST kit and asked to conduct the test relying on the instructions for use. Usability was assessed by documenting errors made and difficulties faced by participants. Acceptability was assessed using an interviewer-administered semi-structured questionnaire.
RESULTS
RESULTS
Among 150 participants, 19% were female and 65.3% had primary level education or lower. 71.3% made at least one error, 56.7% experienced some difficulty during at least one step, and the majority of participants (78%) required assistance during at least one step of the procedure. Most common errors occurred when placing the tube into the stand (18%), collecting the oral fluid sample (24%) and timing of reading results (53%). There was a strong association between presence of symptoms of opiate withdrawals and observed errors (94% vs 62%; p = 0.016) in a sub-group of 74 participants assessed. Inter-reader and inter-operator concordance were 97.7% (kappa: 0.92) and 99.2% (kappa: 0.95), respectively. Acceptability assessed by asking whether participants would choose to use HCVST prior to and after conducting HCVST was 98% and 95%, respectively.
CONCLUSIONS
CONCLUSIONS
We found a high acceptability of oral fluid HCVST among PWID. User errors were common and were associated with the presence of withdrawal symptoms among users. Despite errors, most participants were able to obtain and interpret results correctly. These findings suggest that this group of users may benefit from greater messaging and education including options to receive direct assistance when self-testing for HCV.
Identifiants
pubmed: 36109704
doi: 10.1186/s12879-022-07712-9
pii: 10.1186/s12879-022-07712-9
pmc: PMC9479404
doi:
Substances chimiques
Opiate Alkaloids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
738Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2022. The Author(s).
Références
Diagn Microbiol Infect Dis. 2019 Oct;95(2):149-151
pubmed: 31204109
AIDS. 2019 Feb 1;33(2):353-355
pubmed: 30475267
AIDS Care. 2016 Dec;28(12):1528-1532
pubmed: 27256543
Int J Drug Policy. 2017 Sep;47:137-143
pubmed: 28347636
BMJ Open. 2021 Apr 24;11(4):e041083
pubmed: 33895711
Virol J. 2020 Jan 31;17(1):14
pubmed: 32005264
Harm Reduct J. 2020 Jan 10;17(1):7
pubmed: 31924208
BMC Infect Dis. 2018 Jun 19;18(1):281
pubmed: 29914381
Ann Intern Med. 2017 May 02;166(9):637-648
pubmed: 28319996
Contemp Clin Trials. 2019 Dec;87:105859
pubmed: 31669450
Clin Infect Dis. 2021 Aug 16;73(4):e1018-e1028
pubmed: 34398952
J Hepatol. 2016 Oct;65(1 Suppl):S46-S66
pubmed: 27641988
Diagnostics (Basel). 2021 Feb 23;11(2):
pubmed: 33672241
Clin Liver Dis (Hoboken). 2020 Jul 21;16(1):8-11
pubmed: 32714516
Pan Afr Med J. 2019 Sep 16;34:31
pubmed: 31762899
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
East Afr Med J. 2008 Jul;85(7):318-25
pubmed: 19133420
Diagnostics (Basel). 2021 Mar 07;11(3):
pubmed: 33800060
Sex Health. 2017 Apr;14(2):170-178
pubmed: 27883311
BMC Public Health. 2021 Jun 22;21(1):1188
pubmed: 34158006
BMJ. 2014 Jul 07;348:g3308
pubmed: 25002352
Drug Alcohol Rev. 2012 Nov;31(7):918-24
pubmed: 22612899
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):505-512
pubmed: 29697595
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
J Int AIDS Soc. 2017 Feb 8;20(1):21234
pubmed: 28362073
BMC Infect Dis. 2017 Nov 1;17(Suppl 1):696
pubmed: 29143609
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
Lancet Infect Dis. 2019 Nov;19(11):1255-1263
pubmed: 31540840
BMC Infect Dis. 2021 Oct 14;21(1):1064
pubmed: 34649503
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207
pubmed: 29074409
BMC Med. 2020 Dec 3;18(1):381
pubmed: 33267890